Q-omics provides the consensus-scored MMP28 profile across patient tissues and cancer cell-line models. MMP28 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MMP28 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MMP28 RNA expression shows 22,426 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, COAD, and LSCC as cancer lineages where MMP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMP28 survival associations across molecular data types. MMP28 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMP28 RNA expression–survival associations across cancer types. High MMP28 expression shows unfavorable associations in PAAD, LUSC and KIRP, but favorable associations in ESCA, BRCA and BLCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MMP28 RNA expression.
This table summarizes MMP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MMP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMP28 shows lower tumor expression in COAD, KICH, THCA, UCEC and LUSC and higher tumor expression in HNSC. The COAD box plot shows higher MMP28 RNA expression in normal versus tumor tissue (log2 FC = −3.184, t-test p < 0.001).
This table shows molecular features associated with MMP28 in patient tissues and cancer cell lines. In patient samples, MMP28 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MMP28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
